- Home
- TCRT vs GLMD Comparison
TCRT vs GLMD Comparison
Compare TCRT & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- GLMD
- Stock Information
- Founded
- TCRT 1998
- GLMD 2000
- Country
- TCRT United States
- GLMD Israel
- Employees
- TCRT N/A
- GLMD N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- GLMD Health Care
- Exchange
- TCRT Nasdaq
- GLMD Nasdaq
- Market Cap
- TCRT 7.0M
- GLMD 8.0M
- IPO Year
- TCRT N/A
- GLMD 2014
- Fundamental
- Price
- TCRT $2.84
- GLMD $1.38
- Analyst Decision
- TCRT
- GLMD Hold
- Analyst Count
- TCRT 0
- GLMD 1
- Target Price
- TCRT N/A
- GLMD N/A
- AVG Volume (30 Days)
- TCRT 1.3M
- GLMD 71.3K
- Earning Date
- TCRT 11-13-2025
- GLMD 11-13-2025
- Dividend Yield
- TCRT N/A
- GLMD N/A
- EPS Growth
- TCRT N/A
- GLMD N/A
- EPS
- TCRT N/A
- GLMD N/A
- Revenue
- TCRT $6,000.00
- GLMD N/A
- Revenue This Year
- TCRT $5,680,500.00
- GLMD N/A
- Revenue Next Year
- TCRT N/A
- GLMD N/A
- P/E Ratio
- TCRT N/A
- GLMD N/A
- Revenue Growth
- TCRT N/A
- GLMD N/A
- 52 Week Low
- TCRT $1.31
- GLMD $1.15
- 52 Week High
- TCRT $6.20
- GLMD $4.68
- Technical
- Relative Strength Index (RSI)
- TCRT 49.53
- GLMD 43.71
- Support Level
- TCRT $2.51
- GLMD $1.33
- Resistance Level
- TCRT $3.16
- GLMD $1.44
- Average True Range (ATR)
- TCRT 0.38
- GLMD 0.08
- MACD
- TCRT -0.07
- GLMD -0.01
- Stochastic Oscillator
- TCRT 16.02
- GLMD 15.60
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.